Skip to content

IgA-positive Versus IgA-negative Immune Complex Vasculitis

Retrospective Analysis of Frequency of Systemic Involvement in IgA-positive Cutaneous Immune Complex Vasculitis Versus IgA-negative Cutaneous Immune Complex Vasculitis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01815190
Enrollment
300
Registered
2013-03-20
Start date
2011-01-31
Completion date
2016-12-31
Last updated
2015-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous Vasculitis

Keywords

immune complex vasculitis, cutaneous vasculitis, IgA vasculitis, IgA nephropathy

Brief summary

Cutaneous vasculitis due to vascular deposition of large circulating immune complexes is a disease frequently seen by general practitioners and dermatologists. The clinical symptom is palpable purpura with predilection for the lower legs. In some cases vasculitis also affects systemic organs, such as the kidneys and the intestine. When the immune complexes contain immunoglobulin class A (IgA) and when there is systemic involvement, the disease has been referred to as Henoch Schönlein purpura. When there are no signs of systemic involvement, the disease has been referred to as cutaneous leukocytoclastic angiitis. The investigators hypothesize that palpable purpura with predilection for lower legs is a pathognomonic clinical sign for immune complex vasculitis in both IgA vasculitis and IgA-negative vasculitis, but that only the presence of IgA in immune complexes is likely to be associated with systemic involvement and therefore warrants more extensive diagnostic procedures Vice versa the investigators postulate that the presence of IgG or IgM without IgA in immune complexes excludes systemic involvement The investigators also want to investigate to which of the 2 groups patients with palpable purpura and negative immunofluorescence should be assigned.

Interventions

None listed

Sponsors

University Hospital Muenster
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* histologically proven leukocytoclastic vasculitis * clinically palpable purpura

Exclusion criteria

* no histological confirmation * relevant data missing in file

Design outcomes

Primary

MeasureTime frame
Frequency of systemic involvement in patients with IgA-positive versus patients with non-IgA-positive immune complex vasculitis10 years

Countries

Germany

Contacts

Primary ContactCord Sunderkötter, Prof Dr MD
cord.sunderkoetter@ukmuenster.de+49 251 8357481
Backup ContactIlka Herrgott, MD
+49 251 8356502

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026